P68-4 Feasibility study of a new tissue-based comprehensive genome profiling test

Abstract

Two tissue-based comprehensive genome profiling (CGP) tests (FoundationOne® CDx and OncoGuideTM NCC Oncopanel System) have been introduced into daily clinical practice since June 2019. Currently the CGP test for patients with advanced solid tumor which gets refractory to standard therapies or for which no standard therapy exists are covered by national health insurance system of Japan. Since both CGP tests require at least 20% of tumor cell contents in the specimen, patients whose tissue sample does not meet this criteria cannot undergo tissue-based CGP test.